ONCO
Onconetix Inc
NASDAQ: ONCO · HEALTHCARE · BIOTECHNOLOGY
$0.64
-8.57% today
Updated 2026-05-01
Market cap
$514220.00
P/E ratio
—
P/S ratio
0.63x
EPS (TTM)
$-82.80
Dividend yield
—
52W range
$1 – $54
Volume
9.4M
Onconetix Inc (ONCO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $58465.00 | $2.52M | $815371.00 |
| Revenue growth (YoY) | — | — | — | — | — | +4217.3% | -67.7% |
| Cost of revenue | $573.00 | $3056.00 | $4890.00 | $6752.00 | $1.19M | $1.47M | $182458.00 |
| Gross profit | $-573.00 | $-3056.00 | $-4890.00 | $-6752.00 | $-1.13M | $1.06M | $632913.00 |
| Gross margin | — | — | — | — | -1927.9% | 41.8% | 77.6% |
| R&D | $60174.00 | $524908.00 | $1.33M | $4.13M | $1.95M | $154359.00 | $66133.00 |
| SG&A | — | $1.10M | $2.09M | $9.35M | $14.77M | $11.23M | $7.04M |
| Operating income | $-880230.00 | $-1.62M | $-3.42M | $-13.48M | $-36.03M | $-56.49M | $-6.34M |
| Operating margin | — | — | — | — | -61634.5% | -2238.0% | -778.2% |
| EBITDA | $-821342.00 | $-1.60M | $-3.41M | $-13.41M | $-36.71M | $-57.60M | $-6.33M |
| EBITDA margin | — | — | — | — | -62784.1% | -2281.9% | -776.3% |
| EBIT | $-821915.00 | $-1.60M | $-3.42M | $-13.42M | $-36.75M | $-58.33M | $-6.34M |
| Interest expense | — | — | — | $0.00 | $671625.00 | $1.41M | $751005.00 |
| Income tax | $-3.00 | $-203241.00 | $-4.00 | $-61410.00 | $-12593.00 | $-1.05M | — |
| Effective tax rate | 0.0% | 11.3% | 0.0% | 0.5% | 0.0% | 1.7% | 0.0% |
| Net income | $-821915.00 | $-1.60M | $-3.42M | $-13.42M | $-37.41M | $-58.69M | $-14.03M |
| Net income growth (YoY) | — | -94.6% | -113.7% | -292.7% | -178.8% | -56.9% | +76.1% |
| Profit margin | — | — | — | — | -63986.5% | -2325.2% | -1721.0% |